AN2 Therapeutics, Inc.
Underestimation
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| P/E |
0/10
|
0 | 48.77 | -100% | -5.66 | -100% |
| P/S |
|
0 | 33.77 | -100% |
|
|
| P/BV |
|
3.94 | 4.83 | -18.31% |
|
|
| P/FCF |
|
-6.22 | 61 | -110.19% |
|
|
| Ev/Ebitda |
|
-6.84 | -22.17 | -69.15% |
|
|
| Ev/S |
|
0 | 22.57 | -100% |
|
|
| Ev/FCF |
|
-8.94 | 68.76 | -113% |
|
|
| E/P |
|
-0.1954 | 0.0178 | -1199.38% |
|
|
Efficiency
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Ebitda margin |
0/10
|
0 | 4.97 | -100% | 0 | 0% |
| ROE |
|
-51.91 | 9.61 | -640.08% |
|
|
| ROA |
|
-46.66 | 0.3443 | -13652.49% |
|
|
| ROIC |
|
0 | 7.63 | -100% |
|
|
| ROS |
|
0 | -25.17 | -100% |
|
|
| ROCE |
|
-111.68 | 15.45 | -822.89% |
|
|
Debt
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Debt/Ebitda |
10/10
|
-0.000761 | -3.68 | -99.98% | -0.0289 | -97.37% |
| Nеt Debt/Ebitda |
|
0.2247 | -3.44 | -106.54% |
|
|
| Debt/Ratio |
|
0.000382 | 0.1986 | -99.81% |
|
|
| Debt/Equity |
|
0.000538 | 1.66 | -99.97% |
|
|
| Debt/Net Income |
|
-0.000819 | 10.32 | -100.01% |
|
|
Dividends
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Dividend yield |
0/10
|
0 | 0.541 | -100% | 0 | 0% |
| Number of years of dividend growth |
|
0 | 0.7368 | -100% | ||
| DSI |
|
0 | 0.2256 | -100% |
|
|
| Average dividend growth |
|
0 | 0.9598 | -100% |
|
|
| Average percentage for 5 years |
|
0 | 0.4928 | -100% |
|
|
| Average percentage for payments |
|
0 | 43.56 | -100% |
|
|
| Difference from average difference in sector |
|
-0.541 |
Growth impulse
| Parameter | Grade | Value | Sector average | Difference with sector, % | ||
|---|---|---|---|---|---|---|
| Growth impulse Revenue in 5 years |
0/10
|
0 | -57.64 | -100% | ||
| Growth impulse Ebitda in 5 years |
|
-194.29 | -90.94 | 113.65% | ||
| Growth impulse Net Income in 5 years |
|
1055.93 | -97.8 | -1179.68% | ||
| Growth impulse FCF in 5 years |
|
2031.52 | -108.72 | -1968.58% | ||
| Growth impulse EPS in 5 years |
|
812.16 | -142.05 | -671.74% |
IP Score
3.75/10
